Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, provides targeted treatment for metastatic cancers of the abdomen. This level of precision saves the surrounding tissue, decreasing side effects.
The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with advanced hepatocellular cancer (HCC).
This is an open-label, single-arm, Phase II feasibility study to examine the proportion of patients that complete neoadjuvant therapy followed by curative-intent surgery. Patients with high-risk, resectable, intrahepatic cholangiocarcinoma will receive the combination of gemcitabine, cisplatin, and durvalumab for 4 cycles in the neoadjuvant setting before undergoing surgical resection. After surgery, patients will receive the combination therapy of gemcitabine, cisplatin, and durvalumab for 4 cycles in the adjuvant setting.
Phase II trial evaluating the combination of XL-092 with durvalumab and tremelimumab in unresectable HCC. This phase II trial design will be preceded by a safety lead in of 9-12 patients.
The Mays Cancer Center is exploring holistic therapies and approaches in comprehensive evidence-based prevention, treatment and patient recovery, and expanding services and programs to address the specific needs of patients and family members at each stage of cancer care.
The South Texas community experiences unusually high rates of kidney cancer. At Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, you can access national kidney cancer expertise, close to home. Our surgeons are experts at performing highly technical procedures to treat early and late-stage kidney cancers precisely. A team of skilled specialists (led by a urologic cancer surgeon, vascular surgeon and cardiac surgeon) consults on tumor thrombus surgery to treat cancer that has spread to the major veins.
Ovarian cancer is responsible for more deaths than any other cancers of the female reproductive system and is the fifth leading cause of cancer death.
UT Health San Antonio offers a revolutionary therapy for prostate cancer called Pluvicto®. We are one of the only centers in South Texas to offer this innovative treatment, providing new hope for advanced prostate cancer patients.
Close
